Press Releases
March 19, 2020
TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 26, 2020
TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder to Treat Invasive Pulmonary Aspergillosis (IPA)March 19, 2020
TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder to Treat Invasive Pulmonary Aspergillosis (IPA)
TFF Pharmaceuticals Announces Engagement of J.S. Cole & Associates as Strategic Advisor for Partnering Efforts in JapanMarch 12, 2020
TFF Pharmaceuticals Announces Engagement of J.S. Cole & Associates as Strategic Advisor for Partnering Efforts in Japan
TFF Pharmaceuticals Announces Engagement of Torreya Partners, LLC as Strategic Advisor for Partnering Efforts in China and South KoreaMarch 9, 2020
TFF Pharmaceuticals Announces Engagement of Torreya Partners, LLC as Strategic Advisor for Partnering Efforts in China and South Korea
Ascend Capital Founder Malcolm Fairbairn Appointed to TFF Pharmaceuticals Board of DirectorsJanuary 28, 2020
Ascend Capital Founder Malcolm Fairbairn Appointed to TFF Pharmaceuticals Board of Directors
TFF Pharmaceuticals Reports Continued Progress Across Programs in Corporate UpdateJanuary 28, 2020
TFF Pharmaceuticals Reports Continued Progress Across Programs in Corporate Update
TFF Pharmaceuticals’ Scientific Consultant Robert O. Williams III Named to National Academy of InventorsJanuary 7, 2020
TFF Pharmaceuticals’ Scientific Consultant Robert O. Williams III Named to National Academy of Inventors
TFF Pharmaceuticals to Meet with Investors and Commercial Partners in San Francisco during the JP Morgan Healthcare ConferenceDecember 11, 2019
TFF Pharmaceuticals to Meet with Investors and Commercial Partners in San Francisco during the JP Morgan Healthcare Conference
TFF Pharmaceuticals Reports Third Quarter Results and Provides Business UpdateDecember 9, 2019
TFF Pharmaceuticals Reports Third Quarter Results and Provides Business Update
TFF Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Voriconazole Inhalation Powder, to Treat Invasive Pulmonary Aspergillosis (IPA)November 25, 2019
TFF Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Voriconazole Inhalation Powder, to Treat Invasive Pulmonary Aspergillosis (IPA)